Bortezomib Biotech Pharma Limited 3.5 mg powder for solution for injection clinical trials

An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant eligible multiple myeloma patients

This study is testing a new combination of treatments, including a medicine called belantamab mafodotin, for people recently diagnosed with multiple myeloma. It aims to see how safe the combined treatment is and how it affects blood tests and side effects, especially those affecting the eyes.